ADVENTRX Pharmaceuticals to Present at the 20th Annual Bear Stearns Healthcare Conference
September 04 2007 - 6:00AM
PR Newswire (US)
SAN DIEGO, Sept. 4 /PRNewswire-FirstCall/ -- ADVENTRX
Pharmaceuticals, Inc. (AMEX:ANX), a biopharmaceutical research and
development company focused on commercializing proprietary product
candidates for the treatment of cancer and infectious diseases,
announced today that Evan M. Levine, ADVENTRX's chief executive
officer is scheduled to present at the 20th Annual Bear Stearns
Healthcare Conference on Monday, September 10th, 2007 at 8:30 a.m.
Eastern Daylight Time. The conference takes place in New York at
the Grand Hyatt hotel, September 10 - 11, 2007. About ADVENTRX
Pharmaceuticals ADVENTRX Pharmaceuticals is a biopharmaceutical
research and development company focused on commercializing
proprietary product candidates for the treatment of cancer and
infectious diseases. The Company seeks to improve the performance
and safety of existing treatments by addressing significant
problems such as drug metabolism, bioavailability, excessive
toxicity and treatment resistance. More information can be found on
the Company's web site at http://www.adventrx.com/. Forward Looking
Statements ADVENTRX cautions you that statements included in this
press release that are not a description of historical facts are
forward-looking statements that involve risks and assumptions that,
if they materialize or do not prove to be accurate, could cause
ADVENTRX's results to differ materially from historical results or
those expressed or implied by such forward-looking statements.
These risks and uncertainties include, but are not limited to: the
risk that ADVENTRX will be unable to raise sufficient capital to
fund the projects necessary to meet its anticipated or stated goals
and milestones; the ability to timely enroll subjects in and the
results of ADVENTRX's current and anticipated clinical trials; the
potential for ADVENTRX's product candidates to receive regulatory
approval for one or more indications on a timely basis or at all,
and the uncertain process of seeking regulatory approval; the
market potential for ADVENTRX's product candidates and ADVENTRX's
ability to compete in those markets; and other risks and
uncertainties more fully described in ADVENTRX's press releases and
periodic filings with the Securities and Exchange Commission.
ADVENTRX's public filings with the Securities and Exchange
Commission are available at http://www.sec.gov/. You are cautioned
not to place undue reliance on these forward-looking statements,
which speak only as of the date when made. ADVENTRX does not intend
to update any forward-looking statement, including as set forth in
this press release, to reflect events or circumstances arising
after the date on which it was made. DATASOURCE: ADVENTRX
Pharmaceuticals, Inc. CONTACT: Ioana C. Hone of ADVENTRX
Pharmaceuticals, +1-858-552-0866 Web site: http://www.adventrx.com/
Company News On-Call: http://www.prnewswire.com/comp/920134.html
Copyright
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jul 2023 to Jul 2024